At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ian Flinn (Sarah Cannon Cancer Institute, Nashville, TN) discusses a phase I study of the novel PI3k-?,? inhibitor, duvelisib (IPI-145), in patients with relapsed/refractory indolent non-Hodgkin lymphoma.